Phio Pharmaceuticals Corp Sustainability Reports

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing immuno-oncology therapeutics. The company utilizes its proprietary INTASYL self-delivering RNAi platform to develop targeted gene-silencing therapies aimed at destroying cancer cells.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300KOGMLSPLDVHR52

FIGI: BBG0024FKDB4

5 reports from 2018 to 2023

• Phio Pharmaceuticals Corp 2023 Annual Report on Form 10-K
• Phio Pharmaceuticals Corp 2022 Annual Report
• Phio Pharmaceuticals Corp 2021 Annual Report on Form 10-K
• Phio Pharmaceuticals Corp 2020 Annual Report
• Phio Pharmaceuticals Corp 2018 Annual Report